Core Viewpoint - Federal Pharmaceutical (03933) shares rose over 8% following a positive earnings forecast, with a current price of HKD 17.62 and a trading volume of HKD 598 million [1] Financial Performance - The company anticipates a net profit of approximately RMB 1.85 billion for the six months ending June 30, 2025, compared to a net profit of about RMB 1.491 billion for the same period ending June 30, 2024 [1] - The increase in net profit is primarily attributed to licensing fee income from Novo Nordisk, amounting to approximately RMB 1.1 billion [1] Segment Performance - Despite the overall profit increase, the intermediate product segment's profit decreased by approximately RMB 430 million, and the raw material drug segment's profit declined by about RMB 270 million, partially offsetting the growth [1]

Core Viewpoint - The company expects a net profit of approximately RMB 1.85 billion for the six months ending June 30, 2025, compared to RMB 1.491 billion for the same period in 2024, indicating a significant increase in profitability driven by licensing fee income from Novo Nordisk [1] Financial Performance - The anticipated net profit increase is primarily attributed to licensing fee income of approximately RMB 1.1 billion from Novo Nordisk [1] - However, there is a decline in segment profits, with intermediate products decreasing by approximately RMB 430 million and raw materials decreasing by approximately RMB 270 million compared to the same period in 2024, partially offsetting the overall profit growth [1]

Core Viewpoint - The company expects a net profit of approximately RMB 1,850,000,000 for the six months ending June 30, 2025, an increase from RMB 1,491,000,000 in the same period last year, primarily driven by licensing fee income from Novo Nordisk A/S [1] Financial Performance - The increase in net profit is mainly attributed to licensing fee income of approximately RMB 1,100,000,000 from Novo Nordisk A/S [1] - However, there was a decline in segment profits for intermediates by approximately RMB 430,000,000 and for active pharmaceutical ingredients by approximately RMB 270,000,000, which partially offset the overall profit increase [1]

Core Viewpoint - The company expects a net profit of approximately RMB 1.85 billion for the six months ending June 30, 2025, compared to a net profit of approximately RMB 1.491 billion for the six months ending June 30, 2024, indicating a significant increase in profitability driven by licensing fee income from Novo Nordisk [1] Financial Performance - The anticipated net profit for the first half of 2025 is RMB 1.85 billion, which represents an increase from the RMB 1.491 billion net profit reported for the same period in 2024 [1] - The increase in net profit is primarily attributed to licensing fee income of approximately RMB 1.1 billion from Novo Nordisk [1] - However, there is a decline in segment profits, with intermediate products experiencing a decrease of approximately RMB 430 million and raw materials seeing a decline of approximately RMB 270 million, partially offsetting the overall profit growth [1]

The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告載述的資料僅為本公司管理層現時所得的資料。本集團截至二零二五年六月三十 日止六個月的業績尚未落實，亦未經本公司審核委員會及核數師審閱。本集團截至二零 二五年六月三十日止六個月的最終業績可能與本公告所披露的資料有所不同。 ( 於開曼群島註冊成立的有限公司 ) (股份代號 : 3933) 正面盈利提示 茲根據證券及期貨條例第 XIVA 部及香港聯合交易所有限公司證券上市規則第 13.09 條發 出本公告。 聯邦制藥國際控股有限公司（「本公司」）董事會（「董事會」）謹此知會本公司股東 及潛在投資者，根據本公司及其附屬公司（「本集團」）截至二零二五年六月三十日止 六個月按香港財務報告準則編製的未經審核綜合管理帳目，預期本集團截至二零二五年 六月三十日止六個月的淨溢利約為人 ...

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

格隆汇8月14日丨联邦制药(03933.HK)公告，董事会将于2025年8月28日(星期四)举行会议，其中包括考 虑及批准公司及其附属公司截至2025年6月30日止6个月的中期业绩，及宣派中期股息(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 聯邦制藥國際控股有限公司（「本公司」）董事會（「董事會」）謹此公佈，董事會將 於二零二五年八月二十八日（星期四）舉行會議，其中包括考慮及批准本公司及其附屬 公司截至二零二五年六月三十日止六個月的中期業績，及宣派中期股息（如有）。 承董事會命 聯邦制藥國際控股有限公司 公司秘書 梁永康 香港，二零二五年八月十四日 於本公告日期，董事會成員包括執行董事蔡海山先生、梁永康先生、蔡紹哲女士、方煜 平先生、鄒鮮紅女士及朱蘇燕女士；以及獨立非執行董事張品文先生、宋敏教授及傅秋 實博士。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 (於開曼群島成立之有限公司) (股份代號: 3933) 董事會召開日期 ...

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.02%, with notable stock performances including Jingtai Holdings (02228) up 7.38% and Fosun Pharma (02196) up 6.00% [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.52%, reaching a latest price of 0.97 yuan, with a trading volume of 240.45 million yuan and a turnover rate of 0.62% [3] - Jingtai Holdings announced an expected comprehensive income of no less than 500 million yuan for the six months ending June 30, 2025, representing an increase of at least 387% compared to the same period in 2024 [3] Group 2 - The Hong Kong Innovative Drug Selection ETF reached a new high in scale at 385 million yuan and a new high in shares at 399 million [4] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 22.93 million yuan, totaling 42.28 million yuan [4] - The ETF's management fee is 0.50% and the custody fee is 0.10%, which are among the lowest in comparable funds [5] Group 3 - The HSSCPB index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5] - The top ten weighted stocks in the HSSCPB index account for 78.05% of the total index weight, including companies like BeiGene (06160) and WuXi Biologics (02269) [5]

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 重新提交 公司名稱: 聯邦制藥國際控股有限公司 II. 已發行股份及/或庫存股份變動 呈交日期: 2025年8月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03933 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,800,000,000 | HKD | | 0.01 | HKD | | 38,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,800,000,000 | HKD | | 0.01 | HKD | | 3 ...